Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
3 evidence topics · 7 sources
Summary
Available treatments depend on molecular subtype, prior therapy, and resectability. ASCO recommends first-line pembrolizumab for MSI-H or dMMR disease but does not recommend anti-EGFR therapy for RAS-mutant disease. A systematic review of 53 clinical trials reported limited activity for checkpoint-inhibitor monotherapy or checkpoint-inhibitor combinations in MSS colorectal cancer. The LEAP-017 and IMblaze370 trials did not establish their specified overall-survival benefits. These findings limit extrapolation between biomarker groups and between different kinase-inhibitor and immunotherapy combinations.